TP48. TP048 COVID: ARDS CLINICAL STUDIES | 2021

Outcomes for Severe COVID-19 Disease Following ICU

 
 
 
 
 
 
 
 

Abstract


Rationale: Severe SARS Co-V2 (COVID-19) infections are characterized by ARDS, cytokine storm, and multisystem organ failure. Longterm outcomes of these patients requiring long-term acute care (LTAC) have not been clarified. Given the severity of the initial acute illness, poor longterm outcomes are likely. We hypothesized that patients with severe COVID-19 infections would have outcomes worse than non-COVID-19 patients with multisystem organ failure. We tested this by comparing LTAC outcomes in patients having severe COVID-19 disease with patients without COVID-19 who required LTAC after critical illness. Methods: We conducted a chart review of the 275 COVID-19-positive patients requiring intensive care unit (ICU) care discharged from the Brigham and Women s hospital from January 1-July 31, 2020 and compared them to a cohort of 241 ICU patients requiring LTAC who are part of a quality improvement program to enhance care continuity (CC). Statistical analyses used Student-t tests and Chi-square analyses, with P < 0.05 accepted as statistically significant. Results: 65 of 279 COVID-19 patients required LTAC, with 57 patients discharging to the same LTAC used for CC patients. Similar to prior reports, the proportion of Black (28%) and Hispanic (10%) patients were significantly (P < 0.05) greater in COVID-19 patients compared to the CC patients (9% Black and 6% Hispanic). There were no differences between groups in the average patient age: COVID-19 patients (62 ±14.2) and CC patients (60 ±15) or the proportion of males: COVID-19 patients (37, 64%) compared to the CC patients (137, 57%). At transfer to LTAC, 25% CC patients but only 7% COVID-19 patients required mechanical ventilation (MV), although 90% of the COVID-19 patients had required MV during their acute hospitalization. After LTAC transfer, significantly (P < 0.05) fewer COVID-19 patients (12%) compared to CC patients (28%) required readmission to an acute hospital within 30 days of the acute hospital discharge. Additionally, significantly more (P < 0.05) COVID-19 patients (41, 71%) compared to CC patients (73, 30%) were discharged to home after LTAC. Conclusions: The low rates of early readmission and the high rates of home discharge in the COVID patients compared to the CC patients were unexpected and indicate that COVID-19 patients requiring LTAC have outcomes that are comparable, and possibly better than, similar patients without COVID-19. The possible contributing factors for improved outcomes in COVID-19 patients are unknown but may include a lower burden of comorbid disease in these patients and better pre-morbid functional status.

Volume None
Pages None
DOI 10.1164/AJRCCM-CONFERENCE.2021.203.1_MEETINGABSTRACTS.A2512
Language English
Journal TP48. TP048 COVID: ARDS CLINICAL STUDIES

Full Text